INDUSTRY OUTLOOK

Expanding Diagnostics Business: SCHOTT Signs Agreement to Acquire Applied Microarrays Inc.

Applied Microarrays Inc. | September 30, 2021

SCHOTT MINIFAB, a subsidiary of SCHOTT that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, has had a long-standing close customer relationship with Applied Microarrays Inc. (AMI). Together, they develop biotech substrates for diagnostics applications. The expertise of AMI will further strengthen SCHOTT’s ability to offer a single-source contract manufacturing solution. The deal is expected to close in early October.

Through this acquisition, SCHOTT MINIFAB significantly expands its biosensor printing capabilities. This is of particular importance as demand is growing for the manufacturing of point-of-care microarray consumables, especially in applications such as infectious disease detection.

“We pride ourselves on being an end-to-end partner for the global diagnostics industry. Our expansive offering allows us to provide an integrated single-source collection of value-intensive services and products. With the added bioscience knowledge of AMI, we become an even stronger partner, enhancing our capability in surface modification, functionalization and deposition for both glass and polymer products.”

- Greg Wolters, Head of SCHOTT MINIFAB.

AMI will soon be moving to a larger facility in the Phoenix, Arizona area. Its new location will greatly increase SCHOTT’s manufacturing footprint in the United States to serve its global customer base.

Pioneering – responsibly – together
These attributes characterize SCHOTT as a manufacturer of high-tech materials based on specialty glass. Founder Otto Schott is considered its inventor and became the pioneer of an entire industry. Always opening up new markets and applications with a pioneering spirit and passion – this is what has driven the #glasslovers at SCHOTT for more than 130 years. Represented in 34 countries, the company is a highly skilled partner for high-tech industries: Healthcare, Home Appliances & Living, Consumer Electronics, Semiconductors & Datacom, Optics, Industry & Energy, Automotive, Astronomy & Aerospace. In the fiscal year 2020, its 16,500 employees generated sales of 2.24 billion euros. With the best teams, supported by the best digital tools, the group intends to continue to grow. SCHOTT AG is owned by the Carl Zeiss Foundation, one of the oldest foundations in Germany. It uses the Group's dividends to promote science. As a foundation company, SCHOTT has anchored responsibility for employees, society and the environment deeply in its DNA. The goal is to become a climate-neutral company by 2030.

About Applied Microarrays (AMI)
AMI is a company headquartered in Tempe, AZ, which designs, optimizes and manufactures DNA and protein biosensors, and other microarrays on glass, plastic and semiconductors. AMI operates under ISO 9001 and ISO 13485 certification. Since acquiring GE Healthcare’s microarray business in 2007, AMI has evolved to become a full service provider for RUO and Dx devices.

Spotlight

This is a video on the topic Importance of Biotechnology in Agriculture,and I am trying to describe it properly with slideshow. Referring to the significant role of a transparent approach to the end user’s requirement of healthy products, farmers are required to assure producing the highest quality of the products.

Spotlight

This is a video on the topic Importance of Biotechnology in Agriculture,and I am trying to describe it properly with slideshow. Referring to the significant role of a transparent approach to the end user’s requirement of healthy products, farmers are required to assure producing the highest quality of the products.

Related News

DIAGNOSTICS

Lucid Diagnostics, a Subsidiary of PAVmed, Announced Launch of VA EsoGuard® Study

Lucid Diagnostics | March 25, 2022

Lucid Diagnostics Inc., a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc, announced that investigators at the Louis Stokes Cleveland Department of Veterans Affairs Medical Center had enrolled their first patient in a Department of Defense ("DoD")- Katarina B. Greer, M.D., an associate professor of medicine at Case Western Reserve University School of Medicine in Cleveland, is the lead investigator of the research. Lucid supplies the study with EsoCheck® Esophageal Cell Collection Devices and will conduct EsoGuard testing on the obtained samples. We are proud to be partnering with Dr. Greer and the Cleveland VA on this important investigator-initiated clinical study, The study will add important clinical evidence on the impact of EsoGuard in enhancing early detection of esophageal precancer to prevent esophageal cancer deaths by reserving endoscopy for those with a positive EsoGuard test.” Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer. Despite strong clinical practice guideline recommendations, endoscopy has had limited success as a widespread screening tool for Barrett’s Esophagus (BE), a precursor for esophageal adenocarcinoma, a highly lethal form of esophageal cancer, We hope to demonstrate that a strategy that incorporates initial office-based non-endoscopic testing of at-risk patients with EsoGuard improves endoscopy yield and overall cost-effectiveness.” Dr. Greer. Only around 10% of at-risk GERD patients advised for esophageal precancer (BE) screening undergo traditional, invasive upper gastrointestinal endoscopy (EGD). Over 80% of people who undergo EGD screening have a negative result, subjecting the overwhelming majority of these patients to a complicated, invasive, expensive, and inconvenient surgery requiring anesthesia in a specialist procedure center or hospital. EsoGuard has been demonstrated to be 90% sensitive and specific for identifying esophageal precancer and cancer when done on EsoCheck samples, potentially removing the bulk of these negative EGDs, benefiting patients, providers, and the healthcare system. The trial will include up to 100 Cleveland VA patients who meet the American College of Gastroenterology's criteria for esophageal pre-cancer screening. The research compares two screening strategies: (1) regular EGD screening; and (2) EsoGuard testing followed by EGD exclusively in individuals with a positive EsoGuard result. The trial will determine if utilizing EsoGuard to triage patients to EGD improves overall BE screening rates and decreases the number of EGDs with negative screening results. Additionally, the research will analyze the economic implications for the VA system of these two options.

Read More

MEDICAL

Precision NanoSystems is Now a Part of Danaher's Life Sciences Platform

Cytiva, Pall Corporation | June 02, 2021

Danaher Corporation's Life Sciences platform has acquired precision NanoSystems (PNI). PNI is a global leader in technologies and solutions for developing genetic medicines, including mRNA vaccines and therapeutics. PNI will join Danaher's Life Sciences platform and complement other businesses in the forum, including Cytiva and Pall. "PNI has advanced several exciting innovations, and we're thrilled to welcome this talented team," says Emmanuel Ligner, Danaher Group Executive. "As mRNA has matured as a successful technology in some COVID vaccines, we see huge potential for this technology to accelerate other therapies. The work done thus far by the PNI team will also enable our customers at Cytiva and Pall to take a huge step forward in advancing their science to improve the lives of patients." James Taylor, co-founder, and CEO of Precision NanoSystems, says: "Over the last ten years, PNI has been a leading technology company, enabling the development of genetic medicines. Joining Danaher's Life Sciences platform allows our world-class team to accelerate and expand the work we do to support our customers with comprehensive technology platforms and the expertise to manufacture transformative medicines for the benefit of humanity. With the global reach of the Danaher Life Sciences platform and customers who are leaders in biotechnology, this is an incredible opportunity to bring PNI's innovations to market and expand our impact." The overall mRNA therapeutics and vaccines market was growing rapidly and accelerated with the development of COVID-19 mRNA vaccines. It is anticipated that mRNA technology will be used to develop other vaccines and to treat other conditions of high unmet medical need, such as cancer and genetic diseases. At present, most mRNA therapies and other types of genetic medicines in clinical development are designed to be delivered with the help of lipid nanoparticles (LNPs). PNI's Genetic Medicine Toolkit, including its proprietary GenVoyTM LNP delivery platform and NanoAssemblrTM microfluidic-based nanoparticle manufacturing platform, enables the rapid development of genetic medicines. PNI's validated technologies increase the stability, efficacy, yield, and quality of non-viral genetic medication and lower the barrier to develop these essential medicines. PNI is developing a new center of manufacturing excellence in Vancouver, which will proceed as planned. When complete, the biomanufacturing center will further advance Canadian therapeutic and vaccine manufacturing capabilities, broaden the domestic life sciences sector, create new jobs in the region, and foster a new generation of scientific talent. About Pall Pall Corporation may be a filtration, separation, and purification leader providing solutions to meet customers' critical fluid management needs across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety, and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. About Cytiva Cytiva is a global life science leader with more than 8,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency, and capacity to research and manufacture workflows, enabling the development, manufacture, and delivery of transformative medicines to patients.

Read More

CELL AND GENE THERAPY

Tevogen Bio™ Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy

Tevogen Bio | January 13, 2022

Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, announced that the U.S. Patent and Trademark Office has granted a new patent for the method of preparing COVID-19 peptide specific cytotoxic T cells for the treatment of COVID-19 infection. The patent further reinforces the biotech pioneer’s expanding IP portfolio. “Omicron’s extensive mutations and its subsequent ability to evade antibodies highlights the importance of Killer T cells, which can still recognize and eliminate virus-infected cells. Millions among us suffer from inadequate T cell response for various reasons. After two years of the pandemic and witnessing the challenges posed by the ever-evolving virus, we must explore scientific options beyond our current approaches. CTL therapeutics for large patient populations is not an easy undertaking, but Tevogen’s ability to manufacture hundreds of doses from a single donor gives me hope,” Tevogen CEO Ryan Saadi, M.D., M.P.H The granted patent covers Tevogen’s investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T Lymphocytes therapy, TVGN-489, for high-risk COVID-19 patients. The product is currently undergoing a proof of concept clinical trial at Jefferson University Hospitals in Philadelphia. Trial details are available at Clinical Trials - Tevogen. About TVGN-489 TVGN-489 is a highly purified, SARS-CoV-2-specific cytotoxic CD8+ T lymphocyte product, which detects targets spread across the entire viral genome. These targeted CTLs are expected to recognize and kill off virally infected cells, allowing the body to replace them with healthy, uninfected cells. TVGN-489 demonstrated strong antiviral activity toward SARS-CoV-2 targets in preclinical studies. About Tevogen Bio Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises. Tevogen’s leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.

Read More